Nova Scotia Expands Coverage for Dexcom Continuous Glucose Monitoring Systems as Dexcom Launches New Sensor and Releases Alarming Type 2 Diabetes Report
Residents of Nova Scotia with type 1 or type 2 diabetes who use intensive insulin therapy now have coverage for Dexcom G6 and Dexcom G7 continuous glucose monitoring (CGM) systems, the global leader in real-time continuous glucose monitoring, Dexcom, Inc. has announced. The coverage is provided through the province’s Pharmacare programs and the new income-based Sensor-Based Glucose Monitor initiative.
With the rising prevalence of anxiety and depression in individuals with type 2 diabetes, Dexcom has launched the innovative Dexcom ONE+ CGM device, designed to accurately track real-time glucose readings, thereby contributing to improved diabetes management. In conjunction with this launch, Dexcom has also released the Dexcom State of Type 2 Report, which provides valuable insights into the landscape of type 2 diabetes today.
The Dexcom State of Type 2 Report is the first-of-its-kind study that investigates the preferences and behaviors of individuals living with type 2 diabetes, as well as their caregivers. The report sheds light on the challenges faced by this population and emphasizes the need for better management strategies and support systems.
The expansion of coverage in Nova Scotia for Dexcom G6 and G7 CGM systems is significant in improving the quality of life for individuals with diabetes who use intensive insulin therapy. These CGM systems provide real-time glucose monitoring, offering valuable insights into blood sugar levels and trends, which are crucial for effective diabetes management.
By introducing the Dexcom ONE+ CGM device, Dexcom aims to further enhance diabetes management by offering accurate, real-time glucose readings. This device empowers individuals with diabetes to make informed decisions about their lifestyle choices and treatment plans. The Dexcom State of Type 2 Report serves as a comprehensive resource, highlighting the importance of addressing anxiety and depression in those living with type 2 diabetes and emphasizing the need for tailored support.
The collaboration between Dexcom and Nova Scotia’s Pharmacare programs through the Sensor-Based Glucose Monitor initiative demonstrates a commitment to improving access and affordability of cutting-edge technology for individuals with diabetes. The coverage expansion, along with the launch of the Dexcom ONE+ device and the release of the Dexcom State of Type 2 Report, marks significant strides in addressing the challenges faced by individuals living with diabetes and their caregivers.
Comments